Scarica l'app Stockscreener
22.28
8.29%
1.80
Dopo l'orario di chiusura:
22.28
Precedente Chiudi:
$20.48
Aprire:
$20.54
Volume 24 ore:
371.99K
Relative Volume:
1.02
Capitalizzazione di mercato:
$369.43M
Reddito:
$99.61M
Utile/perdita netta:
$-153.60M
Rapporto P/E:
-1.3546
EPS:
-16.4479
Flusso di cassa netto:
$-152.14M
1 W Prestazione:
-13.13%
1M Prestazione:
-5.91%
6M Prestazione:
+33.31%
1 anno Prestazione:
+152.58%
Intervallo 1D:
$20.21
$22.43
Intervallo di 1 settimana:
$18.36
$25.88
Portata 52W:
$7.15
$43.85
Sutro Biopharma Inc Stock (STRO) Company Profile
Nome
Sutro Biopharma Inc
Settore
Industria
Telefono
650-392-8412
Indirizzo
111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare STRO vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
STRO
Sutro Biopharma Inc
|
22.28 | 339.58M | 99.61M | -153.60M | -152.14M | -16.45 |
VRTX
Vertex Pharmaceuticals Inc
|
515.57 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.86 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
986.80 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
211.94 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.66 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Sutro Biopharma Inc Stock (STRO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-07 | Iniziato | Leerink Partners | Outperform |
| 2026-03-24 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2026-03-24 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2026-01-20 | Aggiornamento | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-06-16 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-03-17 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-03-14 | Downgrade | BofA Securities | Buy → Underperform |
| 2025-03-14 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | Downgrade | Wedbush | Outperform → Neutral |
| 2024-05-08 | Iniziato | BofA Securities | Buy |
| 2023-11-09 | Iniziato | Deutsche Bank | Buy |
| 2023-10-06 | Iniziato | Oppenheimer | Outperform |
| 2023-03-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-08-18 | Ripresa | Wells Fargo | Overweight |
| 2021-06-18 | Iniziato | H.C. Wainwright | Buy |
| 2020-12-03 | Iniziato | Stifel | Buy |
| 2020-09-02 | Iniziato | Jefferies | Buy |
| 2020-07-16 | Iniziato | Wells Fargo | Overweight |
| 2020-01-13 | Iniziato | SunTrust | Buy |
| 2019-10-07 | Iniziato | BTIG Research | Buy |
| 2019-07-18 | Iniziato | Deutsche Bank | Buy |
| 2019-04-29 | Iniziato | H.C. Wainwright | Buy |
| 2018-10-22 | Iniziato | JMP Securities | Mkt Outperform |
| 2018-10-22 | Iniziato | Piper Jaffray | Overweight |
| 2018-10-22 | Iniziato | Wedbush | Outperform |
Mostra tutto
Sutro Biopharma Inc Borsa (STRO) Ultime notizie
Broker Revenue Forecasts For Sutro Biopharma, Inc. (NASDAQ:STRO) Are Surging Higher - simplywall.st
Sutro Biopharma, Inc. (NASDAQ:STRO) Just Reported And Analysts Have Been Lifting Their Price Targets - simplywall.st
Sutro Biopharma, Inc. (NASDAQ:STRO) Given Average Rating of "Buy" by Analysts - MarketBeat
Sutro Biopharma (STRO): Perceptive Advisors reports 7.9% beneficial stake - Stock Titan
Sutro Biopharma (STRO): Point72 group reports 1.4% stake in 13G/A - Stock Titan
Sutro Biopharma Q3 EPS Forecast Reduced by HC Wainwright - MarketBeat
STRO Maintained by Citizens -- Price Target Lowered to $34.00 - GuruFocus
Sutro Biopharma (NASDAQ:STRO) Price Target Lowered to $34.00 at Citizens Jmp - MarketBeat
STRO Reiterated by Wedbush -- Price Target Maintained at $60 - GuruFocus
Sutro Biopharma (NASDAQ:STRO) Earns Outperform Rating from Wedbush - MarketBeat
Citizens cuts Sutro Biopharma stock price target on revenue miss - Investing.com
Citizens cuts Sutro Biopharma stock price target on revenue miss By Investing.com - Investing.com Canada
Sutro Biopharma earnings missed by $0.13, revenue fell short of estimates - Investing.com Canada
Is Sutro Biopharma Inc (STRO) Facing Pressures After Q2 Earnings - GuruFocus
Sutro Biopharma Releases Q2 2026 Financial Results - AlphaStreet
Why is Sutro Biopharma Stock Falling On Wednesday? - TradingView
Sutro Biopharma (NASDAQ:STRO) Posts Quarterly Earnings Results, Misses Expectations By $0.14 EPS - MarketBeat
Sutro Biopharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Sutro Biopharma Reports Q2 2026 Financial Results and Pipeline Update - Kalkine Media
Sutro Biopharma Announces Q2 2026 Financial Results and Updates Corporate Presentation - Kalkine Media
Form 8K Sutro Biopharma For: 12 August By Investing.com - Investing.com Nigeria
Sutro Biopharma Q2 Results Highlight Advancing ADC Pipeline - TipRanks
Sutro reports early clinical responses from STRO-004 cancer trial By Investing.com - Investing.com Australia
SUTRO BIOPHARMA, INC. 2Q 2026: Revenue $9.84M, EPS ($2.33) — 10-Q Summary - TradingView
Sutro Biopharma (STRO) revenue drops as cash rises after $110M stock sale - Stock Titan
Sutro Biopharma Reports $9.8 Million Revenue in Q2 2026 - Quiver Quantitative
Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study - The Manila Times
Sutro Biopharma delivers Q2 2026 financials and advances Phase 1 STRO-004 trial - Traders Union
Sutro Biopharma (STRO) Earnings Date and Reports 2026 $STRO - MarketBeat
Sutro Biopharma (STRO) Edges Higher to $25.53 as Traders Eye Key Resistance at $26.81Stock News - dars.gov.et
Stifel Initiates Sutro Biopharma(STRO.US) With Buy Rating, Announces Target Price $48 - moomoo.com
Sutro Biopharma (STRO) Institutional Ownership 2026 $STRO - MarketBeat
SUTRO BIOPHARMA INC : STIFEL INITIATES COVERAGE WITH BUY RATING; PRICE TARGET $48 - Bitget
Stifel initiates Sutro Biopharma stock with buy on ADC platform By Investing.com - Investing.com Australia
Stifel initiates Sutro Biopharma stock with buy on ADC platform - Investing.com
BlackRock, Inc. Adds to Sutro Biopharma Inc (STRO) Stake -- Shar - GuruFocus
Perceptive Advisors LLC Invests $17.82 Million in Sutro Biopharma, Inc. $STRO - MarketBeat
Sutro Biopharma Inc (STRO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
BlackRock, Inc. (NASDAQ: STRO) reports 6.4% ownership in Sutro Biopharma - Stock Titan
Sutro Biopharma (STRO) Surges as Volume Supports Bullish MomentumHigh Conviction Picks - dars.gov.et
ADAR1 Capital Management LLC Purchases 457,364 Shares of Sutro Biopharma, Inc. $STRO - MarketBeat
Eversept Partners LP Trims Stake in Sutro Biopharma, Inc. $STRO - MarketBeat
Sutro Biopharma Inc (STRO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Sutro Biopharma (STRO) Climbs 5.24% as Biotech Sentiment ImprovesTake Profit Levels - po-news-eg.net
STRO|Sutro Biopharma Inc|Price:23.918|Chg%:+1.038 - TradingKey
STRO|Sutro Biopharma Inc|Price:24.170|Chg%:-0.650 - TradingKey
Sutro Biopharma Inc (STRO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Sutro Biopharma Inc (STRO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Sutro Biopharma Inc (STRO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Sutro Biopharma Inc (STRO) Institutional Confidence - TradingKey
Sutro Biopharma Inc (STRO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Sutro Biopharma Inc Azioni (STRO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Sutro Biopharma Inc Azioni (STRO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Pauling David | Chief Admin. Ofcr. & GC |
Mar 04 '26 |
Option Exercise |
0.00 |
675 |
0 |
10,025 |
| Chung Jane | Chief Executive Officer |
Mar 04 '26 |
Option Exercise |
0.00 |
788 |
0 |
21,567 |
| Pauling David | Chief Admin. Ofcr. & GC |
Mar 02 '26 |
Option Exercise |
0.00 |
2,356 |
0 |
10,320 |
| Pauling David | Chief Admin. Ofcr. & GC |
Mar 01 '26 |
Option Exercise |
0.00 |
1,342 |
0 |
8,515 |
| Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER |
Mar 02 '26 |
Option Exercise |
0.00 |
2,843 |
0 |
10,688 |
| Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER |
Mar 01 '26 |
Option Exercise |
0.00 |
1,125 |
0 |
8,308 |
| Chung Jane | Chief Executive Officer |
Mar 02 '26 |
Option Exercise |
0.00 |
7,750 |
0 |
23,558 |
| Chung Jane | Chief Executive Officer |
Mar 01 '26 |
Option Exercise |
0.00 |
3,188 |
0 |
17,079 |
2.67%
0.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):